185 related articles for article (PubMed ID: 11408535)
1. Modulation of 1,3-bis-(2-chloroethyl)-1-nitrosourea resistance in human tumor cells using hammerhead ribozymes designed to degrade O6-methylguanine DNA methyltransferase mRNA.
Zhang Q; Ohannesian DW; Kreklau EL; Erickson LC
J Pharmacol Exp Ther; 2001 Jul; 298(1):141-7. PubMed ID: 11408535
[TBL] [Abstract][Full Text] [Related]
2. Hammerhead ribozyme-mediated sensitization of human tumor cells after treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Zhang Q; Ohannesian DW; Erickson LC
J Pharmacol Exp Ther; 2004 May; 309(2):506-14. PubMed ID: 14742745
[TBL] [Abstract][Full Text] [Related]
3. Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents.
Kokkinakis DM; Ahmed MM; Delgado R; Fruitwala MM; Mohiuddin M; Albores-Saavedra J
Cancer Res; 1997 Dec; 57(23):5360-8. PubMed ID: 9393761
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional repression of O6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N'-bis(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells.
Ma LC; Kuo CC; Liu JF; Chen LT; Chang JY
Mol Pharmacol; 2008 Aug; 74(2):517-26. PubMed ID: 18492797
[TBL] [Abstract][Full Text] [Related]
5. Ribozyme-mediated modulation of human O6-methylguanine-DNA methyltransferase expression.
Potter PM; Harris LC; Remack JS; Edwards CC; Brent TP
Cancer Res; 1993 Apr; 53(8):1731-4. PubMed ID: 8467487
[TBL] [Abstract][Full Text] [Related]
6. Extended O6-methylguanine methyltransferase promoter hypermethylation following n-butylidenephthalide combined with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on inhibition of human hepatocellular carcinoma cell growth.
Yu YL; Yu SL; Su KJ; Wei CW; Jian MH; Lin PC; Tseng IH; Lin CC; Su CC; Chan DC; Lin SZ; Harn HJ; Chen YL
J Agric Food Chem; 2010 Feb; 58(3):1630-8. PubMed ID: 20043672
[TBL] [Abstract][Full Text] [Related]
7. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents.
Srivenugopal KS; Shou J; Mullapudi SR; Lang FF; Rao JS; Ali-Osman F
Clin Cancer Res; 2001 May; 7(5):1398-409. PubMed ID: 11350911
[TBL] [Abstract][Full Text] [Related]
8. Alterations in S-adenosylhomocysteine metabolism decrease O6-methylguanine DNA methyltransferase gene expression without affecting promoter methylation.
Hermes M; Geisler H; Osswald H; Riehle R; Kloor D
Biochem Pharmacol; 2008 Jun; 75(11):2100-11. PubMed ID: 18395186
[TBL] [Abstract][Full Text] [Related]
9. Reversal of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced severe immunodeficiency by transduction of murine long-lived hemopoietic progenitor cells using O6-methylguanine DNA methyltransferase complementary DNA.
Maze R; Kapur R; Kelley MR; Hansen WK; Oh SY; Williams DA
J Immunol; 1997 Jan; 158(2):1006-13. PubMed ID: 8993023
[TBL] [Abstract][Full Text] [Related]
10. Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo.
Moritz T; Mackay W; Glassner BJ; Williams DA; Samson L
Cancer Res; 1995 Jun; 55(12):2608-14. PubMed ID: 7780976
[TBL] [Abstract][Full Text] [Related]
11. Regulation of expression of the DNA repair gene O6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling.
Boldogh I; Ramana CV; Chen Z; Biswas T; Hazra TK; Grösch S; Grombacher T; Mitra S; Kaina B
Cancer Res; 1998 Sep; 58(17):3950-6. PubMed ID: 9731508
[TBL] [Abstract][Full Text] [Related]
12. Both extraneuronal monoamine transporter and O(6)-methylguanine-DNA methyltransferase expression influence the antitumor efficacy of 2-chloroethyl-3-sarcosinamide- 1-nitrosourea in human tumor xenografts.
Chen ZP; Wang ZM; Carter CA; Alley MC; Mohr G; Panasci LC
J Pharmacol Exp Ther; 2001 Mar; 296(3):712-5. PubMed ID: 11181897
[TBL] [Abstract][Full Text] [Related]
13. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors.
Kuo CC; Liu JF; Chang JY
J Pharmacol Exp Ther; 2006 Feb; 316(2):946-54. PubMed ID: 16258022
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow-derived cells exhibiting lung epithelial cell characteristics are enriched in vivo using methylguanine DNA methyltransferase-mediated drug resistance.
Reese JS; Roth JC; Gerson SL
Stem Cells; 2008 Mar; 26(3):675-81. PubMed ID: 18192231
[TBL] [Abstract][Full Text] [Related]
15. Ribozyme and free alkylated base: a dual approach for sensitizing Mex+ cells to the alkylating antineoplastic drug.
Mariani L; Citti L; Nevischi S; Eckstein F; Rainaldi G
Cancer Gene Ther; 2000 Jun; 7(6):905-9. PubMed ID: 10880022
[TBL] [Abstract][Full Text] [Related]
16. Effects of streptozotocin/bis-chloroethylnitrosourea combination therapy on O6-methylguanine DNA methyltransferase activity and mRNA levels in HT-29 cells in vitro.
Pieper RO; Futscher BW; Dong Q; Erickson LC
Cancer Res; 1991 Mar; 51(6):1581-5. PubMed ID: 1825618
[TBL] [Abstract][Full Text] [Related]
17. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
Phillips WP; Willson JK; Markowitz SD; Zborowska E; Zaidi NH; Liu L; Gordon NH; Gerson SL
Cancer Res; 1997 Nov; 57(21):4817-23. PubMed ID: 9354444
[TBL] [Abstract][Full Text] [Related]
18. Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU.
Schold SC; Kokkinakis DM; Rudy JL; Moschel RC; Pegg AE
Cancer Res; 1996 May; 56(9):2076-81. PubMed ID: 8616853
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of O6-methylguanine-DNA-methyltransferase on mammalian cells.
Li DB; Wang JS; Fang Q; Sun HY; Xu W; Li WD
Chin Med J (Engl); 2007 Apr; 120(8):714-7. PubMed ID: 17517190
[TBL] [Abstract][Full Text] [Related]
20. Tetrazepinones are equally cytotoxic to Mer+ and Mer- human tumor cell lines.
Jean-Claude BJ; Mustafa A; Watson AJ; Damian Z; Vasilescu D; Chan TH; Leyland-Jones B
J Pharmacol Exp Ther; 1999 Feb; 288(2):484-9. PubMed ID: 9918549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
